Immune checkpoints and cancer development: Therapeutic implications and future directions

Area of Science:

• Immunology and Oncology
• Cancer Immunotherapy

Background:

• Immune checkpoints, such as CTLA-4 and PD-1, regulate anti-tumor immune responses.
• Approved immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 are used for various cancers.
• The tumor microenvironment contains other inhibitory checkpoints like LAG-3, TIM-3, TIGIT, and BTLA.

Purpose of the Study:

• To review recent findings on immune checkpoints beyond PD-1 and CTLA-4.
• To explore the role of monoclonal antibodies targeting these novel immune checkpoints in cancer immunotherapy.
• To summarize ongoing clinical trials for advanced solid tumors and hematologic malignancies.

Main Methods:

• Literature review of recent scientific findings on immune checkpoints.
• Analysis of the role of monoclonal antibodies in targeting novel immune checkpoints.
• Summary of clinical trial data for emerging immunotherapies.

Main Results:

• Several novel immune checkpoints (LAG-3, TIM-3, B7-H3, VISTA, DGK-α, TIGIT, BTLA) show inhibitory effects on lymphocytes.
• These checkpoints exhibit synergistic suppression with PD-1, offering new therapeutic opportunities.
• Monoclonal antibodies targeting these novel checkpoints are in clinical trials for various cancers.

Conclusions:

• Emerging immune checkpoints represent promising targets for next-generation cancer immunotherapy.
• Targeting these novel checkpoints, often in combination with PD-1 blockade, may overcome resistance and improve treatment outcomes.
• Further research and clinical trials are crucial to establish the efficacy and safety of these novel immunotherapies.